Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2014-02-01
2025-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
NCT00897481
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
NCT01205815
German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)
NCT03125707
Clinical Tumor Anemia Registry (TAR)
NCT01795690
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
metastatic melanoma
1,000 subjects with metastatic melanoma stage III or IV suitable for systemic treatment from centers of the German Dermatologic Cooperative Oncology Group (DeCOG)
molecular tissue analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
molecular tissue analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clinically eligible for systemic cancer therapy (immune checkpoint inhibitors, targeted agents).
3. Tumor tissue biopsy already existing (metastasis tissue as recent as possible, but older tissue material or primary tumor tissue also possible).
4. Patient has given written informed consent for the current study as well as for his data to be entered into the ADOREG online database system.
5. Patient is ≥18 years old.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dermatologic Cooperative Oncology Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dirk Schadendorf, MD
Role: STUDY_CHAIR
Dermatologic Cooperative Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of Dermatology, University Hospital Tuebingen
Tübingen, Baden-Wurttemberg, Germany
Department of Dermatology, ElbeKliniken - Klinikum Buxtehude
Buxtehude, Lower Saxony, Germany
Department of Dermatology, The Saarland University Hospital
Homburg/Saar, Saarland, Germany
Dept. of Dermatology, University of Schleswig-Holstein, Campus Lübeck
Lübeck, Schleswig-Holstein, Germany
Dept. of Dermatology, Helios Clinic Erfurt
Erfurt, Thuringia, Germany
Department of Dermatology, University Hospital
Augsburg, , Germany
Department of Dermatology, University Hospital
Dresden, , Germany
Department of dermatology, University Hospital
Essen, , Germany
Medizinische Hochschule,dermatologische Klinik und Poliklinik
Hanover, , Germany
Department of Dermatology
Ludwigshafen, , Germany
Skin Cancer Unit, University Hospital
Mannheim, , Germany
Department of Dermatology, University Hospital
Minden, , Germany
Department of Dermatology
Oberhausen, , Germany
Department of Dermatology
Quedlinburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Patrick Terheyden, MD
Role: primary
Rudolf herbst, MD
Role: primary
Julia Welzel
Role: primary
Friedegund Meier
Role: primary
Selma Ugurel
Role: primary
Inke Grimmelmann, MD
Role: primary
Edgar Dippel
Role: primary
Jochen Utikal
Role: primary
Ralf Gutzmer
Role: primary
Alexander Kreuter
Role: primary
Jens Ulrich
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA209-578
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.